Inokuchi, Masafumi http://orcid.org/0000-0001-8886-9517
Kutomi, Goro
Kijima, Yuko
Sakai, Takehiko
Sawaki, Masataka
Shien, Tadahiko
Hanamura, Noriko
Yano, Kenji
Wada, Noriaki
Saji, Shigehira
Iwata, Hiroji
Article History
Received: 3 September 2019
Accepted: 28 November 2019
First Online: 12 December 2019
Change Date: 19 May 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12282-021-01256-7
Compliance with ethical standards
:
: M Inokuchi, G. Kutomi, Y. Kijima, T. Sakai, M. Sawaki, T. Shien, N. Hanamura, K. Yano, and N. Wada have no conflicts of interest. S. Saji reports grants and personal fees (honoraria for lectures) from Eisai, grants and personal fees from Chugai, grants and personal fees from Astra Zeneca, grants and personal fees from Takeda, grants and personal fees from Novartis, grants and personal fees from Taiho, personal fees from Kyowahakko Kirin, personal fees from Pfizer, personal fees from Daiichi Sankyo, grants and personal fees from Nihon Kayaku, grants from Ono, outside the submitted work;. S. Saji is executive board member of Japan Breast cancer Research Group (JBCRG) and Japanese Breast Cancer Society (JBCS). H. Iwata reports grants and personal fees from Chugai, personal fees from AstraZeneca, personal fees from Daiichi Sankyo, grants and personal fees from Novartis, grants from MSD, grants and personal fees from Lilly, personal fees from Kyowa Hakko Kirin, personal fees from Pfizer, during the conduct of the study; However, H. Iwata confirm total fee from each company is not over the limited fee determined by JBCS. H. Iwata is executive board member of JBCS.